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Introduction
Systemic lupus erythematosus (SLE) is a prototypic auto-
immune disease characterized by the production of 
autoantibodies directed against nuclear self-antigens. Th  e 
role of genetic variation has been extensively investigated 
in lupus, reveal  ing polymorphisms throughout the 
genome corre  lated with disease [1-3]. Although studies 
investigating common genetic variants in lupus have 
revealed a number of susceptibility loci, the cumulative 
eﬀ  ect size of these loci accounts for a small fraction of 
disease heritability, approximately 15 to 20% [4]. Th  e 
inability of present genetic association studies to 
comprehensively account for disease heritability has led 
many to postulate that the missing heritability of complex 
human disease may broadly reside in epigenetic 
mechanisms [5].
Epigenetics refers to heritable modiﬁ  cations that regu-
late gene expression without changes to DNA sequence 
[6]. Common epigenetic mechanisms include DNA 
methy  lation and histone modiﬁ  cation. MicroRNAs are 
also involved in epigenetic regulation. Th  e most widely 
researched epigenetic modiﬁ   cation to date is DNA 
methy  lation, which is known to have diverse regulatory 
function, governing gene expression patterns in a cell- 
and tissue-speciﬁ   c manner. Broadly speaking, DNA 
methylation is a negative regulator of gene expression 
whereby higher levels of promoter and CpG island 
methylation are typically observed to correlate with lower 
levels of gene expression. Aberrant DNA methylation 
and gene expression are observed in a number of 
conditions and diseases, including cancer, neuro-
psychiatric disorders, and autoimmunity.
DNA methylation patterns are established during 
develop  ment and maintained throughout the life course 
by a class of enzymes known as DNA methyltransferases 
[7]. Further, widespread epigenomic diﬀ  erences are ob-
served throughout cellular development [8,9]. Once 
estab  lished, patterns of DNA methylation are heritably 
preserved from parent to daughter cells during replica-
tion by DNA methyltransferase 1 (DNMT)1. DNMT1 
associates with replication fork complex proteins where 
it transfers methylation patterns from the template 
strand to the incipient copy.
Histone proteins act to spatially organize chromatin 
and determine the extent to which chromatin is 
accessible for active transcription. Covalent modiﬁ  cation 
of histone proteins represents another facet of epigenetic 
variation through which gene expression and chromatin 
structure are regulated. Methylation and acetylation of 
speciﬁ   c histone lysine residues act to regulate the 
transcriptional state of chromatin in cis. Locus-speciﬁ  c 
chromatin architecture varies between cell types, as 
genes are diﬀ  erentially expressed among diﬀ  erent cells at 
speciﬁ  ed times.
Epigenetic regulation acts to program gene expression 
patterns in the various cell types that comprise the tissues 
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epigenetic modiﬁ  cation facilitates the diﬀ  erentiation of 
diverse cell types from static genomic DNA. Th  e 
possibility for epigenetic variation underlying the disease 
process of lupus is intriguing as patients experience 
periods of calm punctuated by disease ﬂ  ares. Because 
epigenetic states vary with time and between cell types, it 
is in the context of disease activity that epigenetic 
variation in lupus is likely to stand in sharpest relief 
against the epigenome of normal tissues.
Epigenetic regulation in normal lymphocytes
Th   e human immune system is composed of a number of 
cell types that serve speciﬁ  c functions in establishing and 
maintaining cell-mediated and humoral immunity. Th  e 
diversity of lymphocyte populations that comprise the 
human immune system is established and maintained 
through epigenetic modiﬁ   cation. Distinct and highly 
conserved epigenetic proﬁ   les of DNA methylation are 
observed in normal B and T lymphocytes [10,11]. While 
DNA methylation patterns are broadly conserved within 
cell types, widespread diﬀ  erences are observed between 
lymphocyte subtypes. DNMT1 function and DNA 
methy  lation patterns are essential in ensuring T cell 
diﬀ  er  entiation and function [12]. DNA methylation and 
histone modiﬁ  cations reinforce repressive and permissive 
chromatin states at key regulatory loci in CD4+ T cells 
lineages [13,14].
Demethylation and changes in chromatin architecture 
at transcription factor and cytokine genes accompany 
eﬀ   ector cell diﬀ   erentiation in response to cytokine 
signaling among lymphocyte populations. Chromatin 
remodel  ing of the IL17 locus is observed upon diﬀ  eren-
tiation of Th   17 cells [15]. Likewise, DNA demethylation 
and histone acetylation of the IFNG (IFN-γ) and the IL4-
IL5-IL13 genetic loci, upon Th   1 and Th  2  diﬀ  erentiation, 
respectively, is mediated by T cell lineage-speciﬁ  c trans-
cription factors following T-cell receptor signaling [16]. 
Indeed, Th  2-speciﬁ  c chromatin remodeling and demethy-
la  tion takes place in a locus control region that ﬂ  anks a 
number of Th   2 cytokines [17]. Further, these epigenetic 
changes are accompanied by changes in long-range inter-
actions and chromatin architecture at cytokine gene loci 
under Th   1 and Th   2 polarizing conditions [18].
Drug-induced lupus points to epigenetic 
dysregulation in autoimmunity
While approximately 90% of lupus cases are idiopathic, 
prolonged exposure to certain medications is known to 
induce lupus. It was eventually discovered that 
procainamide and hydralazine, medications that can 
cause lupus, inhibit DNA methylation in T cells [19]. It 
was further shown that in vitro treatment of Th  2 cells 
with procainamide or 5-azacytidine (a DNA methylation 
inhibitor) leads to their autoreactivity, and upon adoptive 
transfer these cells are capable of inducing autoimmunity 
in mice [20].
A better understanding of the mechanisms through 
which drug-induced lupus occurs has provided insight 
into the epigenetic mechanisms and pathways involved in 
idiopathic lupus. Global hypomethylation of genomic 
DNA is observed in CD4+ T cells of lupus patients [21]. 
Th  is decline is attributable to a reduction in methyl-
transferase activity. Procainamide acts as a competitive 
inhibitor of DNMT1 [22]. Hydralazine reduces DNA 
methylation via inhibiting extracellular signal-regulated 
kinase (ERK) pathway signaling [23], which regulates the 
expression of DNMT1 [24,25]. Th   e ERK pathway further 
ensures proper immune cell development and function 
[26].
Reduced ERK pathway signaling in lupus CD4+ 
T cells
An ERK pathway signaling defect has been observed in 
lupus CD4+ T cells [27,28] and has been attributed to 
originate from decreased signaling through protein kinase 
C delta in lupus CD4+ T cells [29]. Decreased protein 
kinase C signaling may further account for defective 
T cell activation in lupus [30]. Additionally, mice lacking 
the protein kinase C delta gene display germinal center 
formation in the absence of stimulation and develop 
autoimmunity [31].
A reduction of ERK pathway signaling leading to 
reduced expression of DNMT1 has been shown to lead to 
T cell autoreactivity. Mice that express a dominant-nega-
tive form of the ERK pathway component MEK show 
reduced ERK pathway signaling and reduced expression 
of DNMT1. Th   is leads to overexpression of methylation-
sensitive genes, anti-double stranded DNA antibody 
produc  tion, and activation of IFN-regulated signaling 
pathways similar to lupus patients [32].
Sex-chromosome complement and skewed X 
chromosome inactivation in lupus
Lupus is a sexually dimorphic autoimmune disease with a 
9:1 female bias, a fact that makes sex chromosome 
complement and skewed X chromosome inactivation 
interesting candidates for investigating the origins of the 
disease. Under normal circumstances, females have only 
one X chromosome from which genes are actively trans-
cribed, while the additional X chromosome remains 
transcriptionally inactive through epigenetic repression. 
As previously stated, widespread demethylation of 
genomic DNA is observed in lupus CD4+ T cells, and 
this, it is thought, might lead to the reactivation of 
methylation-sensitive genes on the normally inactive X 
chromosome. An example of the reactivation of a gene 
on the inactive X chromosome in lupus CD4+ T cells is 
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stimulatory molecule that, upon binding with CD40, 
promotes B cell activation, plasma cell diﬀ  erentiation, 
immunoglobulin production and antibody class switch-
ing [33,34]. Overexpression of CD40LG is observed in 
lupus CD4+ and CD8+ T cells as well as lupus B cells 
[35]. CD4+ T cells from women but not men overexpress 
CD40LG when treated with 5-azacytidine, while the 
overexpression of autosomal methylation-sensitive genes 
is comparable between the sexes [36]. CD40LG-trans-
fected normal human T cells lead to autologous B cell 
activation and plasma cell diﬀ  erentiation in co-culture 
assays [37]. Further, T cells from women but not men 
increase B cell IgG production when treated with DNA 
methylation inhibitors, which can be inhibited by anti-
CD40LG antibody [37].
Th   ere is evidence for skewed X chromosome inactiva-
tion in a number of other autoimmune diseases apart 
from lupus, including autoimmune thyroiditis and sclero-
derma, many of which also have a strong female bias [38]. 
Further evidence for the role of sex chromosome comple-
ment in the pathogenesis of lupus comes from 
Klinefelter’s syndrome (47, XXY), a condition in which 
phenotypic male individuals possess an additional X 
chromosome. It was found that lupus is approximately 14 
times more frequent among men with Klinefelter’s 
syndrome than it is among (46, XY) men, a rate similar to 
that observed among women [39].
Aberrant methylation and gene expression in 
lupus CD4+ T cells
Global reduction of DNA methylation is a hallmark of 
CD4+ T cells in lupus (Figure 1). Several autosomal genes 
are known to be hypomethylated in lupus CD4+ T cells. 
Many of these genes encode proteins involved in processes 
related to immune function and inﬂ   ammation. It is 
thought that the overexpression of methylation-sensitive 
genes leads to lupus T cell autoreactivity and subsequent 
induction of autoreactive B cell immunoglobulin 
production.
Lymphocyte function-associated antigen 1 (LFA-1) is a 
multi-unit, integrin family protein involved in lympho-
cyte adhesion that is composed of the products of two 
genes,  CD11a and CD18. DNA methylation and local 
chromatin architecture regulate the tissue-speciﬁ  c  ex-
pres sion  of  CD11a [40]. Promoter hypomethy  lation of 
the ITGAL (CD11a) gene is observed in lupus CD4+ T 
cells [41]. Th  is leads to overexpression of LFA-1 among 
an autoreactive T-cell subset. Further, ectopic expression 
of CD18 recapitulates the eﬀ  ects of treatment with any of 
the multiple DNA methylation inhibitors in inducing T-
cell autoreactivity [42]. LFA-1 overexpression is a driver 
of autoreactivity directly linked to reduced levels of DNA 
methylation.
CD70 (TNFSF7) is a membrane bound, B-cell co-
stimulatory protein involved in regulating B-cell immuno-
globulin production. CD70 is overexpressed in lupus 
CD4+ T cells and T cells treated with DNA methylation 
inhibitors, and this overexpression stimulates B cell IgG 
production in vitro [43]. Indeed, the promoter sequence 
of CD70 that demethylates upon treating normal CD4+ T 
cells with DNA methylation inhibitors is similarly 
demethylated in lupus CD4+ T cells [44]. Reduced 
methylation of a CpG island in the CD70 promoter was 
also observed to correspond with higher CD70 expres-
sion and reduced DNMT1 mRNA levels in MRL/lpr mice 
at 16 weeks when autoimmunity is established [45]. 
Over  expression of CD70 in response to reduced pro-
moter methylation is also observed in patients with 
subacute cutaneous lupus erythematosus. Increased 
expression was observed at both the mRNA and protein 
level by ﬂ   ow cytometry, and although the overall 
proportion of CD70-expressing cells was unchanged, the 
mean ﬂ  orescent intensity was greater among subacute 
cutaneous lupus erythematosus patient samples [46].
Many transcription factors are known to inﬂ  uence local 
chromatin architecture through speciﬁ  c interaction with 
DNA and histone methyltransferases. Decreased levels of 
RFX1 at CD11a and CD70 promoters leads to decreased 
methylation and increased expression of both of these 
genes in lupus CD4+ T cells [47]. Moreover, this change 
in DNA methylation and expression is reinforced by con-
comitant reductions in histone 3 lysine 9 trimethylation 
(H3K9me3) at these promoters in a RFX1-SUV39H1 
interaction-dependent manner [48].
A role for the Gadd45A (growth arrest and DNA-
damage-inducible 45 alpha) gene in autoimmunity has 
long been suggested. Initial knock-out studies of 
Gadd45a reported by Salvador and colleagues revealed a 
protective role for the gene product, as knockout 
Gadd45A-/- mice grew to develop a lupus-like systemic 
autoimmune disease [49]. More recently, transfection of 
HEK293 cells with a Gadd45A overexpression vector was 
shown to result in both site-speciﬁ   c and global DNA 
demethylation. Further, increased expression of Gadd45A 
following exposure to ultraviolet light was shown to lead 
to reduced genomic DNA methylation, a trend partially 
counteracted by knockdown of Gadd45A [50]. Th  ese 
ﬁ   ndings were recapitulated in recent work in CD4+ 
T cells in which overexpression of Gadd45A and expo-
sure to UV-B light radiation led to increased expression 
and promoter demethylation of CD70 and CD11a [51].
Perforin is a protein encoded by the PRF1 gene, 
expressed primarily by CD8+ T lymphocytes and natural 
killer cells. Perforin acts to promote target cell lysis by 
promoting the formation of pores in the target cell 
membrane. Initially, overexpression of perforin in T cells 
was observed in response to treatment with DNA 
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perforin overexpression were accompanied by changes in 
chromatin architecture as evidenced by the gain of a 
DNAse hypersensitive site upstream of the PRF1 trans-
cription start site [52]. Further, this trend of PRF1 
promoter demethylation leading to increased perforin 
expression was then conﬁ  rmed in lupus CD4+ T cells, 
where increased perforin was observed via ﬂ  ow cyto  metry 
in CD4+ T cells of lupus patients with active disease [53].
Killer immunoglobulin-like receptors (KIRs) comprise 
a diverse set of polymorphic genes involved in HLA type 
I stimulatory and inhibitory signals in natural killer cells 
and CD4+ CD28- T cells [54]. Expression of KIR genes is 
regulated by methylation of their promoter regions, and 
Figure 1. Epigenetics of lupus CD4+ T cells. A broad DNA methylation defect is observed in lupus CD4+ T cells. Reduced expression of DNA 
methyltransferase 1 (DNMT1) is observed to lead to the hypomethylation and overexpression of several genes in lupus CD4+ T cells. Specifi  cally, 
hypomethylation of promoter regions of CD70, CD11a, PRF1, CD40LG (CD40 ligand), and killer immunoglobulin-like receptor (KIR) genes leads to 
their overexpression and subsequent induction of T-cell autoreactivity. Further, overexpression of GADD45A (growth arrest and DNA-damage-
inducible 45 alpha) contributes to decreased DNA methylation in lupus CD4+ T cells. There is overlap between the DNA methylation defect in lupus 
and other epigenetic mechanisms. Overexpression of miR-148a and miR-126 aff  ect DNA methylation levels by directly targeting DNMT1 transcripts. 
miR-21 overexpression also aff  ects DNA methylation; however, this microRNA indirectly regulates DNMT1 expression through ERK pathway 
signaling. Variable expression of other individual regulatory microRNAs also contributes to the disease process. Overexpression of miR-17-92 in 
murine T lymphocytes is observed and may aff  ect lymphocyte stability. miRNA-155 is overexpressed in CD4+ T cells and contributes to reduced 
stability of regulatory T cell populations. miR-31 negatively regulates the expression of Foxp3 and has been observed to be overexpressed in murine 
splenocytes. Underexpression of miR-146 leads to increased type I IFN signaling in lupus CD4+ T cells. Reduced expression of miR-125a leads to 
increased expression of the infl  ammatory chemokine RANTES by reduced targeting of KLF13 transcripts. Overexpression of miR-101 has been 
reported in murine T lymphocytes. miR-101 has also been reported to negatively regulate EZH2, a histone methyltransferase involved in epigenetic 
repression. Aberrant patterns of histone modifi  cation are also observed in lupus CD4+ T cells. Reduced levels of histone 3 lysine 9 trimethylation 
(H3K9me3) are observed as well as reduced p300 histone acetyltransferase activity. Further, EZH2 levels are reduced in lupus CD4+ T cells. Reduced 
levels of the transcription factor RFX1 lead to loss of local epigenetic repression characterized by reduced levels of DNA methylation and H3K9me3 
via the histone methyltransferase SUV39H1.
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of a number KIR genes [55]. Interestingly, overexpression 
of KIR genes is also observed in lupus CD4+ T cells, and 
this overexpression is seen to correspond to disease 
activity [56].
DNA methylation in lupus B cells
Several genes are observed to be diﬀ  erentially regulated 
in lupus B cells. Surface expression of CD5, which is 
important in maintaining B cell anergy [57], is known to 
be reduced in lupus B cells. IL-6 has been observed to 
alter CD5 expression levels in lupus B cells by inhibiting 
DNA methylation [58]. Increased exposure to IL-6 leads 
to ERK pathway inhibition, decreased DNMT1 levels, 
and increased expression of CD5-1EB, the cytoplasmic 
form of CD5, which in turn limits the expression of CD5 
on the cell surface. Th  is trend was observed in lupus B 
cells and conﬁ  rmed among B cells from healthy controls 
exposed to increased levels of IL-6 or treated with DNA 
methylation inhibitors [58].
Widespread DNA methylation diff  erences between 
lupus patients and healthy controls
Studies in disease-discordant monozygotic twins are 
useful when investigating epigenetic aspects of complex 
human disease. Monozygotic twin studies enable the 
control of many of the confounding inﬂ  uences of genetic 
variation, although there is evidence for copy number 
variation among monozygotic twins [59], while focusing 
on disease-relevant, inter-individual epigenetic variation. 
Monozygotic twins display signiﬁ  cant life course varia-
tion in epigenetic modiﬁ  cations, and this variation, it is 
thought, may drive disease pathogenesis [60]. A recent 
twin study in lupus revealed signiﬁ  cant epigenetic varia-
tion in white blood cells between disease-discordant 
monozygotic twins [61]. Th   e study reported and validated 
a number of genes found to possess promoter methy-
lation diﬀ  erences. Speciﬁ  cally, 49 genes were found to be 
hypomethylated in lupus patients, highlighting ontologies 
relevant to autoimmunity. In addition, variable methy-
lation of ribsomal genes was reported whereby 18S and 
28S ribosomal subunit genes are hypomethylated in lupus 
individuals of discordant pairs and hypomethylated in 
both individuals of concordant lupus twin pairs examined.
A recent case-control methylation study utilizing high-
throughput methylation arrays identiﬁ   ed a number of 
diﬀ   erentially methylated genes and pathways in lupus 
CD4+ T cells. Th   e methylation status of over 27,000 CpG 
sites in promoter regions of nearly 15,000 genes was 
collected and analyzed for 12 female lupus cases and 12 
controls. In the study, Jeﬀ   ries and colleagues report 
hypo  methylation of 236 CpG sites and hypermethylation 
of another 105 (representing 232 and 104 genes, respect-
ively). Among hypomethylated genes, ontology analysis 
highlighted genes involved in connective tissue develop-
ment, including ADAMTS1, ALX4, CD9, ESRRA, FGF8, 
HOXA13, HOXD11, MMP9, MSX1, PDGFRA, and SOX5 
[62]. Hypermethylation of genes involved in folate bio-
synthesis, a pathway related to maintenance of DNA 
methy  lation, was observed [62]. Interestingly, RUNX3, 
which belongs to a transcription factor family involved in 
mediating cell proliferation signals [63], was found to be 
hypermethylated in lupus CD4+ T cells. Protein inter-
action network analysis also revealed diﬀ  erential methy-
lation of several apoptosis-associated genes, and genes 
involved in cell growth, tissue development, and cell 
division. Th  is study also provided data to support a 
potential role for some speciﬁ   c DNA methylation 
changes as novel biomarkers for lupus disease activity, 
with the caveat that these need to be ﬁ  rst validated and 
then examined in the setting of a clinical trial before 
being considered of any clinical beneﬁ  t (Figure 2).
Variable regulation of microRNAs in lupus
MicroRNAs represent a post-transcriptional regulatory 
mechanism whereby single-stranded RNAs 20 to 24 bp in 
length homologously bind to mRNA transcripts, eﬀ  ect-
ively blocking their subsequent translation [64]. MicroRNA 
regulatory networks work to ﬁ  ne-tune immune function. 
Further, diﬀ  erential regulation of microRNAs appears to 
play a role in the disease process of lupus.
MiR-146, which plays a role in negatively regulating 
innate immune responses [65], has been observed to be 
intrinsically underexpressed in lupus CD4+ T cells. 
Reduced expression of miR-146 leads to induction of 
type I interferon signaling, and miR-146 expression levels 
negatively correlate with disease activity. Interestingly, 
IFN signatures of lupus patient peripheral blood mono-
nuclear cells were alleviated upon transfection with a 
miR-146 expression vector [66]. Zhao and colleagues 
observed targeting of the 3’ UTR of the KLF13 gene by 
miR-125a in a dose-dependent manner. Underexpression 
of miR-125a was also reported in lupus CD4+ T cells 
leading to increased levels of the inﬂ  ammatory chemo-
kine RANTES [67]. Normalization of miR-125a 
expression in CD4+ T cells of lupus patients resulted in 
reduced RANTES levels.
Investigation of microRNA patterns in three models of 
murine lupus reveals common microRNA pathways. Th  e 
study investigated common defects in regulatory 
microRNAs among splenic T and B lymphocytes in B6/
lpr, MRL/lpr, and NZB/W mice when compared with 
their respective age-matched control mice. Dai and 
colleagues report a number of regulatory microRNAs, 
including miR-155, miR-150, miR-182-96-183, miR-31, 
miR-127, and miR-379, to be signiﬁ  cantly increased in 
splenic B and T cells of MRL/lpr mice. Signiﬁ  cantly, 
upregulation of miR-146, miR101a, and miR-17-92 in 
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cytes [68]. Mice with increased miR-17-92 expres  sion 
display uncontrolled expansion and auto  immunity 
characterized by reductions in the pro  apoptotic protein 
Bim and the tumor suppressor PTEN (phosphatase and 
tensin homolog) [69]. Interestingly, genomic loss of 
miR-101 has been associated with over  expression of the 
repressive histone methyl  trans  ferase EZH2 in human 
prostate cancer cells [70]. EZH2, the histone 
methyl  trans  ferase that mediates H3K27me3, functionally 
asso  ciates with DNMT1 [71]. Overexpres  sion of miR-101 
might contribute to the loss of repression observed in 
lupus CD4+ T cells. Moreover, down  regulation of EZH2 
in CD4+ T cells has been reported in lupus patients with 
active disease [72].
A systematic, microarray-based investigation of micro-
RNA expression in Epstein-Barr virus-transformed B cell 
lines of lupus patients with nephritis and controls in 
Figure 2. Genome-wide methylation studies in lupus. (a) Diff  erences in promoter DNA methylation were investigated in the context of identical 
genetic background (that is, discordant monozygotic (MZ) twins). Javierre and colleagues [61] performed a genome-wide methylation scan 
investigating epigenetic diff  erences in fi  ve pairs of monozygotic twins discordant for lupus. The study investigated these diff  erences in white blood 
cells (WBCs) of patients and their related controls. The study reported variable methylation of 49 of the 807 genes investigated. Pathway analysis 
of these genes reveals putative functions in immune response, cell activation, and cell proliferation. The study further identifi  es hypomethylation 
and overexpression of ribosomal genes, which may correspond to increased ribosomal-autoantibody formation. (b) Jeff  ries and colleagues [62] 
investigated the methylation status of over 27,000 individual CpG dinucleotides located in promoter regions of nearly 15,000 genes. Twelve 
lupus cases of varying disease activity and healthy control individuals were included in the study. The study reports hypomethylation of CpG 
dinucleotides in 232 genes and the hypermethylation of 104 genes. Pathway analysis reveals genes involved in folate biosynthesis, a pathway 
related to maintenance of DNA methylation. Further, modifi  cations of individual genes observed to be dysregulated included the hypomethylation 
of CD9, encoding a known activator of T cell signaling, and hypermethylation of RUNX3, which encodes a transcription factor that mediates 
profi  leration signals in lymphocytes. In both of the diagrams on the left side of each panel, empty red circles represent unmethylated CpG 
dinucleotides, whereas solid blue circles represent methylated CpG sites. In the lower panel, the diff  erences in color of the gene body indicate the 
presence of genetic heterogeneity.
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reproducible overexpression of a number of microRNAs 
across ethnicities [73]. Th  is study also included a 
discordant monozygotic twin pair in which the broader 
microRNA expression patterns were partially conserved.
More recently, analysis of microRNA expression 
proﬁ   les in lupus peripheral blood mononuclear cells 
compared to controls revealed the diﬀ  erential expression 
of 27 microRNAs out of 365 analyzed [74]. Importantly, 
the levels of miR-21, miR-25, miR-106b and miR-148b 
correlated with disease activity in lupus patients, while 
miR-196a and miR-379 expression inversely correlated 
with disease activity, suggesting a potential role for 
microRNA proﬁ  ling as disease biomarker in lupus [74].
A recent comprehensive review on the role of micro-
RNA in the pathogenesis of lupus and other autoimmune 
disease has been recently published [75].
Crosstalk between microRNAs and DNA 
methylation in lupus
Targeting of DNA methyltransferases by regulatory micro-
RNAs is observed in both development and disease. 
MicroRNAs appear to play a critical role in regu  lation of 
de novo methylation in mouse embryonic stem cells [76]. 
Targeting of DNMT3a and DNMT3b by miR-29 family 
members is observed in human lung cancer [77]. Two 
recent studies demonstrate down  regulation of DNMT1 as 
a result of variable expression of regulatory microRNAs in 
lupus.
Pan and colleagues [78] demonstrated a connection 
between aberrant regulation of certain microRNAs and 
reduced expression of DNMT1. A genome-wide micro-
RNA scan in both lupus patients and MRL/lpr lupus-
prone mice revealed increased expression of both miR-21 
and miR-148a. miR-21 targets and inhibits RSGRP1, a 
signaling molecule involved in the ERK signaling path-
way, through which it is able to indirectly downregulate 
DNMT1 expression. MiR-148a, however, directly targets 
the DNMT1 transcript.
MiR-126 is among a number of microRNAs observed 
to be variably regulated in lupus CD4+ T cells. Zhao and 
colleagues [79] report overexpression of miR-126 in 
lupus CD4+ T cells, which correlates with decreased 
DNMT1 expression. Th  ey further demonstrate that 
miR-126 targets a 3’ UTR region in DNMT1 and reduces 
DNMT1 protein expression. Furthermore, ectopic over-
expression of miR-126 in CD4+ T cells from healthy 
donors led to hypomethylation and overexpression of the 
methylation sensitive genes CD11a and CD70 and 
induction of T cell autoreactivity [79].
Variable histone protein modifi  cation in lupus
Covalent modiﬁ   cation of histone protein represents 
another layer of epigenetic regulation. Acetylation of 
histone tails leads to an open conformation of chromatin 
that is permissive to gene expression. Th  e acetyl  trans-
ferase activity of p300 in B cells is crucial in preventing 
autoimmunity. Mice with a B cell-speciﬁ  c  knock-in 
mutant version of p300 that lacks only histone acetyl-
transferase activity develop a lupus-like autoimmune 
disease characterized by splenomegaly, nephritis, and 
vasculitis [80]. Reduced global levels of H3K9me3 and 
histone 3 acetylation have been reported in lupus CD4+ 
T cells, and diﬀ  erences in the activity of histone acetyl-
trans  ferases have been observed in lupus CD4+ T cells 
[72].
Sullivan and colleagues [81] initially reported variability 
in histone 4 acetylation at the tumor necrosis factor alpha 
(TNF-α) locus in lupus monocytes. Th  is same group 
further studied histone 4 acetylation at the genome level 
in lupus monocytes where they found hyperacetylation 
and overexpression of several genes with modest overlap 
with the acetylation and expression patterns of IFN-α 
treated cells [82]. Th  ese ﬁ   ndings point to widespread 
changes in chromatin architecture in lupus monocytes.
The altered epigenetic state of regulatory T cell 
populations in murine lupus
Foxp3+ CD25high regulatory T cells broadly serve to 
suppress autoimmunity. Expression of the transcription 
factor Foxp3 regulates the diﬀ   erentiation of the regu-
latory T cell lineage [83]. Mice that lack Foxp3 display a 
paucity of regulatory T cells and subsequently develop 
fatal autoimmunity [84]. Epigenetic modiﬁ  cations regu-
late the emergence and durability of regulatory T cells. 
Demethylation of the Foxp3 promoter accompanies the 
emergence of the regulatory T cell lineage in both mice 
and humans [85,86]. Foxp3 expression is also governed 
post-transcriptionally by microRNAs. Speciﬁ  cally, miR-31 
is a negative regulator of Foxp3 expression, while miR-21 
positively regulates Foxp3 [87].
Regulatory T cells of lupus patients with active disease 
are reduced in quantity commensurate to disease severity 
and display decreased suppressive function [88,89]. 
Divekar and colleagues [90] have recently reported a 
regulatory T cell defect of murine lupus whereby regu-
latory T cells exhibit reduced suppressive potential in 
MRL/lpr mice that is further characterized by decreased 
dicer expression and increased miR-155 expression. 
Interestingly, miR-155 plays a critical role in the 
regulation of germinal center formation and is critical in 
maintaining proper immune function [91,92]. Divekar 
and colleagues suggest that increased expression of 
miR-155 may account for the regulatory T cell defect 
observed in MRL/lpr mice. Th  ese  ﬁ  ndings  further 
coincide with previous reports in which dicer deﬁ  ciency 
among regulatory T cells led to diminished regulatory 
T cell populations and autoimmune pathology [93,94].
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consequence?
Th  is review oﬀ  ers clear evidence of the involvement of 
epigenetic variation in lupus. Th  e studies mentioned 
herein describe widespread lupus-associated epigenetic 
variation, yet association and causation are not inter-
changeable terms. Many questions regarding the causal 
nature of epigenetic variation in lupus remain to be 
answered. At what stage of disease are epigenetic mani-
festations ﬁ  rst present? In what cell type(s) do epigenetic 
perturbations ﬁ   rst appear in lupus? Does epigenetic 
variation merely reﬂ  ect prior canalization of disease, or 
are these modiﬁ   cations ultimately causal? Is disease-
associated epigenetic variation a proximate or an ultimate 
cause of disease?
Th   e causal nature of epigenetic variation in lupus is a 
complicated question. In our view, large longitudinal 
cohort studies that will allow the epigenome to be 
examined before and after disease will be crucial to 
answer this question. Of course, these types of studies 
will be complicated to design, and samples from speciﬁ  c 
cell types will have to be maintained and subsequently 
examined. Th   e evidence that inhibiting T cell ERK path-
way signaling using a mouse model results in decreased 
DNMT1 expression, overexpression of methylation 
sensitive genes similar to lupus patients, the development 
of anti-double stranded DNA antibody, and an interferon 
signature-like gene expression proﬁ   le represents the 
strongest argument for a causal role of DNA methylation 
in lupus to date [32]. Recent studies have shown that 
epigenetic variation in lupus occurs along multiple axes. 
Unraveling the causal web of lupus epigenetics has 
become an increasingly complicated task as recent 
studies have revealed a complex, interconnected network 
of epigenetic regulation that leads to altered gene 
expression in lupus. Th  ese studies pose new questions 
about the nature of complexity of regulatory events 
involved in lupus pathogenesis. Future epigenetic studies 
Table 1. Epigenetic perturbations observed in lupus T cells
Gene/pathway  Epigenetic defect   Cell type  Consequence  Reference
ERK pathway  Defective signaling  Human and murine T cells  Reduced DNMT1 expression and reduced T cell DNA   [23,32]
     methylation
PRF1  Hypomethylation  CD4+ T cells  Increased perforin expression  [52,53]
ITGAL  Hypomethylation  CD4+ T cells  Increased CD11a expression  [40,41]
CD40LG  Hypomethylation  CD4+ T cells  B-cell hyperactivation  [36]
KIR2DL4 (KIR)  Hypomethylation  CD4+ T cells  Increased KIR expression   [55,56]
TNFSF7  Hypomethylation  CD4+ T cells  Increased CD70 expression  [43-45]
GADD45A  Overexpression  CD4+ T cells  Decreased DNA methylation  [51]
Folate biosynthesis  Hypermethylation  CD4+ T cells  Impaired DNA methylation?  [62]
RUNX3  Hypermethylation  CD4+ T cells  Impaired T cell proliferation?  [62]
CD9  Hypomethylation  CD4+ T cells  Increased T cell activation?  [62]
MMP9 Hypomethylation  CD4+  T  cells  ?  [62]
PDGFRA Hypomethylation  CD4+  T  cells  ?  [62]
SOX5 Hypomethylation  CD4+  T  cells  ?  [62]
miR-126  Overexpression  CD4+ T cells  Downregulation of DNMT1  [79]
miR-146  Underexpression  CD4+ T cells; murine   Increased type I IFN  [66,68]
   T  splenocytes
miR-17-92  Overexpression  Murine T splenocytes  Lymphocyte stability  [68]
miR-155  Overexpression  CD4+ T cells; CD4+ CD25+   Reduced Treg cell stability  [90]
   T  cells
miR-101a  Overexpression  Murine T splenocytes  Reduced EZH2?  [68]
miR-31  Overexpression  Regulatory T cells; murine   Repression of FOXP3  [62,87]
   T  splenocytes
miR-21  Overexpression  CD4+ T cells  Targets ERK pathway leading to lower DNMT1  [78]
miR-125a Underexpression  CD4+  T  cells  Targets  KLF13 leading to increased RANTES  [67] 
miR-148a  Overexpression  CD4+ T cells  Downregulates DNMT1  [78]
RFX1  Underexpression  CD4+ T cells  Reduced H3K9me3 and DNA methylation  [47,48]
CD40LG, CD40 ligand; DNMT, DNA methyltransferase; ERK, extracellular signal-regulated kinase; GADD45A, growth arrest and DNA-damage-inducible 45 alpha; 
H3K9me3, histone 3 lysine 9 trimethylation; KIR, killer immunoglobulin-like receptor; Treg, regulatory T cell.
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therefore need to incorporate multiple-level systems 
modeling and complexity science to uncover disease 
etiology in complex and dynamic biologic systems.
Determining the environmental-epigenetic interactions 
that contribute to lupus is important in understanding 
the ultimate cause of lupus. Th  ere is much reference 
made to environmental factors in the lupus epigenetics 
literature, yet these typically refer to a few examples or 
are invoked as an unknown explanatory variable. With a 
few notable exceptions, the speciﬁ  c mechanisms through 
which environmental triggers operate remain largely 
uncharacterized to date. Further characterization of the 
putative environmental-epigenetic tipping point between 
active and inactive disease is therefore needed.
Conclusion
Studies to date have revealed a substantial epigenetic 
component of disease in lupus, particularly in T cells 
(Table 1, Figure 1), yet ultimately the causal nature of 
disease associated epigenetic variation remains ambiguous. 
Although the etiology of lupus is indeterminate, some 
generalizations about the origins of lupus can be made: 
ﬁ   rst, there is a signiﬁ   cant genetic component to the 
disease; second, known genetic variation does not 
comprehensively describe the origin, development, and 
even the heritability of the disease; third, epigenetic 
variation correlates with variable expression of a number 
of genes in pathways involved in disease pathogenesis; 
and fourth, lupus is the result of complex interactions 
between genetic susceptibility, environmental exposure, 
and epimutation. Th  e path forward in understanding 
lupus is not merely in the clear delineation of the various 
components of disease but in understanding emergent 
phenotypes that result from their interaction over time.
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